When a quality ASX 200 share hits a 52-week low, I think it is worth paying attention.
Sometimes the market is sending a warning. Other times, short-term disappointment creates a better entry point into a business that still has strong long-term prospects.
This week, two popular ASX 200 shares have fallen to 52-week lows.
And while I would be happy to buy and hold them both at these prices, there are risks to consider.
Image source: Getty Images
Wesfarmers Ltd (ASX: WES)
Wesfarmers is one of the ASX 200 shares I would be most comfortable holding through different market conditions.
The blue-chip stock owns a collection of businesses with strong positions in their categories, including Bunnings, Kmart, Officeworks, Priceline, and industrial operations.
I think Bunnings remains the jewel in the crown. It has a powerful market position in home improvement and a brand that many Australians trust. Even when consumer spending is under pressure, people still need to maintain, repair, and improve their homes.
Kmart gives Wesfarmers a different kind of strength. Its value-focused retail model can remain highly relevant when households are looking to stretch their budgets further.
What I like most about Wesfarmers is the quality of its capital allocation. The company has a long record of investing where it sees attractive returns and keeping discipline when opportunities do not stack up.
The shares are rarely cheap for long. So, when the market gives investors a chance to buy them at a 52-week low, I think it is worth a close look.
CSL Ltd (ASX: CSL)
CSL is the most difficult of the two to assess right now.
The biotech giant has been hammered after downgrading its guidance, and I think investors are right to question the outlook. The business has disappointed, confidence has been damaged, and its quality is being tested in a way we have not seen for a long time.
CSL now expects FY26 revenue of around US$15.2 billion and NPATA of around US$3.1 billion on a constant currency basis, excluding restructuring costs and impairments. It has also flagged approximately US$5 billion of additional non-cash pre-tax impairments across FY26 and FY27, including CSL Vifor intangible assets and selected property, plant, and equipment.
That is not easy to overlook. But I still think CSL could be worth buying and holding for patient investors.
The company remains a global healthcare leader with exposure to plasma therapies, influenza vaccines, and specialist medicines. Its interim CEO has acknowledged that outcomes have fallen short of expectations, but also pointed to strengths in plasma collection, influenza vaccines, cash flow, and financial capacity.
There is also still a long-term demand story in immunoglobulin. CSL's presentation notes mid to high single digit demand growth and significant unmet patient need across key indications.
I would not pretend the turnaround will be quick. CSL needs to rebuild trust, sharpen execution, and prove that its transformation can restore profitable growth. But at a 52-week low, I think a lot of bad news is now reflected in the share price.
Foolish takeaway
A 52-week low does not automatically make a share a bargain.
But I think Wesfarmers and CSL shares are worth considering for patient investors.
Wesfarmers offers high-quality retail exposure and disciplined capital management, while CSL offers long-term healthcare assets that I believe will still have material value if management can restore confidence.
For investors willing to look beyond near-term weakness, these are beaten-down ASX 200 shares I would be happy to buy and hold.
